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Abstract
Introduction: Hereditary causes of visceral thrombosis or thrombosis should be sought among young patients. We 
present a case of a young man presenting with multiple hepatic infarctions resulting in portal hypertension due to 
homozygosity of the prothrombin gene mutation not previously described in literature.
Case presentation: A 42-year-old Caucasian man with a previous history of idiopathic deep vein thrombosis 11 years 
earlier presented with vague abdominal pains and mildly abnormal liver function tests. An ultrasound and computed 
tomography scan showed evidence of hepatic infarction and portal hypertension (splenic varices). A thrombophilia 
screen confirmed a homozygous mutation for the prothrombin gene mutation, with mildly reduced levels of anti-
thrombin III (AT III). Subsequent testing of his father and brother revealed heterozygosity for the same gene mutation.
Conclusion: Hepatic infarction is unusual due to the rich dual arterial and venous blood supply to the liver. In the 
absence of an arterial or haemodynamic insult causing hepatic infarction, a thrombophilia should be considered. To 
our knowledge, this is the first reported case of a hepatic infarction due to homozygosity of the prothrombin gene 
mutation. It is unclear whether homozygotes have a higher risk of thrombosis than heterozygotes. In someone 
presenting with a first thrombosis with this mutation, the case for life-long anticoagulation is unclear, but it may be 
necessary to prevent a second and more severe second thrombotic event, as occurred in this case.
Introduction
Thrombophilia is an acquired or inherited tendency for
recurrent thrombotic episodes. There is no obvious clini-
cal reason for thrombosis. However, an inherited factor
should be considered, especially in patients who have
their first idiopathic venous thromboembolism before the
age of 50, recurrent thrombotic episodes, or a first degree
relative with thrombosis before the age of 50 [1].
Inherited thrombophilia can be due to inactive variants
of endogenous anticoagulants (protein C, S and anti-
thrombin III). Or, very rarely, it can be due to overactive
variants of normal procoagulants, such as dysfibrinoge-
naemia and the relatively recently described prothrombin
gene variant. Factor V Leiden is the most common vari-
ant, accounting for up to 40% of cases [2].
The prothrombin gene variant is a mutation (transition
of guanine to adenine) at nucleotide 20210 of the pro-
thrombin gene. Heterozygous carriers of this mutation
have elevated plasma prothrombin and are prone to
venous thrombotic episodes [3].
We describe the case of a 42-year-old man who pre-
sented with abdominal pain attributed to multiple
hepatic infarctions who had a combination of homozy-
gosity for the prothrombin gene variant and mild defi-
ciency of antithrombin III (AT III).
Case presentation
A 42-year-old Caucasian man presented with a one-year
history of worsening vague abdominal pains over the past
few months. The pain radiated to his back, and was asso-
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ciated with fever. He did not smoke and his alcohol con-
sumption was 25 units per week.
At the age of 31 years, he had a right spontaneous lower
limb deep vein thrombosis (DVT), with post-phlebitic leg
swelling. His father had previously had two spontaneous
DVTs, and his brother, aged 30, had a DVT following a
herniorrhaphy.
An examination and investigations revealed a normal
blood pressure and pulse. There was generalised upper
abdominal tenderness, but no guarding or rebound. His
cardiorespiratory examination was unremarkable. His
blood tests revealed the following: bilirubin 21 μmol/L
(normal range 5-17 μmol/L), aspartate aminotransferase
(AST) 50 IU/L (normal range <40 IU/L), alkaline phos-
phatise (ALKP) 271 U/L (normal range <105 IU/L),
gamma glutamyl transferase (GGT) 150 IU/L (normal
range <35 IU/L), amylase 25 U/L, international norma-
lised ratio (INR) 1.1, prothrombin time (PT) 27.4, C-reac-
tive protein (CRP) 114 mg/L (normal range <4 mg/L),
erythrocyte sedimentation rate (ESR) 53 mm/hr, normal
full blood count (platelets 190 × 109/L) and normal renal
function.
There was no growth in the blood culture. Serology for
Epstein-Barr virus, hepatitis A virus and hepatitis C virus
was negative. An autoimmune screen was negative (rheu-
matoid arthritis, antinuclear antibody, anti-mitochon-
drial antibody, anti-liver kidney microsomes, anti-
s m o o t h  m u s c l e  a n t i b o d y ) .  A n  u l t r a s o u n d  s c a n  o f  t h e
patient's abdomen showed mild splenomegaly with a
trace of ascites.
During a follow-up in clinic two months later, he com-
plained of increased lethargy with reduced appetite. A
unilateral leg oedema was noticed. A gastroscopy was
normal and a computed tomography (CT) scan con-
firmed splenomegaly (13.5 cm), though he had a normal
liver and had no ascites. An ultrasound Doppler examina-
tion showed a chronic DVT with incomplete recanalisa-
tion. Repeat blood tests resulted in the following: ALT 38
IU/L, ALKP 77 IU/L, bilirubin 22 μmol/L, AST 27 IU/L,
GGT 58 IU/L, thrombocytopenia (78 × 106/mm3) and
neutropenia (1.65 × 106/mm3), ESR 5 mm/hr.
Six months later, the patient experienced persisting
vague abdominal pain, thrombocytopenia and a mild
abnormality of the liver function tests. A repeat liver
ultrasound showed a new 3 cm echo-poor area in the
periphery of segment VIII, consistent with an infarct.
A repeat CT scan six months later showed multiple
infarcts in the liver, numerous dilated veins on the greater
and lesser curves of his stomach, splenic hilum, and sur-
rounding the portal vein, consistent with portal hyper-
tension.
A thrombophilia screen for anticardiolipin antibodies,
lupus anticoagulant, protein C and protein S deficiency,
factor V Leiden mutation and paroxysmal nocturnal hae-
moglobinuria were all negative. He was found to be
homozygous for the prothrombin G20210A mutation
with mild deficiency for antithrombin III (AT III 73%,
normal range 80%-120%). His father and brother were
subsequently tested and found to be heterozygous for the
prothrombin gene variant. He was started on life-long
warfarin.
Discussion
Prothrombin is encoded by a 21-kb-pair gene localised
on chromosome 11. Poort et al. identified a transition
(guanine to adenine) at nucleotide 20210 in the 3'
untranslated region of the prothrombin gene as a risk fac-
tor for thrombosis [4]. This is possible because the vari-
ant prothrombin is resistant to degradation.
Heterozygotes for the variant have 30% increased plasma
prothrombin levels [4,5].
T h e  l e v e l  o f  t h r o m b o t i c  r i s k  i n  h o m o z y g o t e s  i s  n o t
known as only a few cases have been reported [4,6,7], but
their prothrombin levels are not always raised [8]. A
young Mexican male homozygote suffered a myocardial
infarction, ilio-femoral venous thrombosis and massive
pulmonary embolism [9]. In contrast to this, two
homozygotes had no thrombosis, suggesting that the
mutation alone is less risky than other genetic risk factors
[6].
Visceral vein thrombosis is rare but quite typical of
inherited thrombophilia [9], especially mesenteric vein
occlusion [10-13]. Heterozygotes have been reported
with Budd-Chiari syndrome [10], hepatic vein thrombo-
sis [12], or portal and mesenteric vein thrombosis [11,13].
But this is the first report of G20210A homozygosity for
the prothrombin gene variant and mild deficiency of AT
III affecting the liver.
A hepatic infarction is rare because of the richly anasta-
mosing collateral arterial supply, and the dual blood sup-
ply from the portal vein and hepatic artery. In this case,
there was portal hypertension as evidenced by splenom-
egaly, thrombocytopenia, and peri-gastric venous varices.
The portal vein may have thrombosed and recanalised,
similar to the patient's leg DVT and the hepatic infarct,
which must have resulted from the interruption of both
the arterial and venous blood supply, which is usually
needed for such an injury in the absence of an established
cirrhosis.
Conclusion
Individuals who are heterozygotes for multiple prothrom-
botic mutations are prone to thromboses. But the deci-
sion to offer anticoagulation must be based on clinical
manifestations. However, combinations of factor V
Leiden and protein C deficiency, protein S deficiency or
AT III deficiency greatly increase the risk of severe and
recurrent thrombosis [14]. The four-year risk of recur-Emmanuelle et al. Journal of Medical Case Reports 2010, 4:122
http://www.jmedicalcasereports.com/content/4/1/122
Page 3 of 3
rent DVT for 20210A heterozygotes is no greater than
that for non-thrombophilic DVT patients [15,16]; but a
10-year follow-up study showed the risk to be increased
2.4 fold [17].
There is at present insufficient evidence pointing to a
need for life-long anticoagulation of heterozygous carri-
ers of the prothrombin gene mutation after a single epi-
sode of DVT. But in this case, there was limb DVT and a
visceral thrombosis with secondary portal hypertension
justifying life-long anticoagulation.
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